Sirolimus Safe Adjunct to Pulsed Dye Laser in Port Wine Stain

This article originally appeared here.
Share this content:
Sirolimus Safe Adjunct to Pulsed Dye Laser in Port Wine Stain
Sirolimus Safe Adjunct to Pulsed Dye Laser in Port Wine Stain

WEDNESDAY, Nov. 4, 2015 (HealthDay News) -- Adjunct topical sirolimus seems to be safe and effective in combination with pulsed dye laser (PDL) for treatment of port wine stain (PWS), according to a case study published online Oct. 26 in Lasers in Surgery and Medicine.

Thomas D. Griffin Jr., M.D., from the Thomas Jefferson University Hospital in Philadelphia, and colleagues describe the utility of adjunct topical sirolimus to reduce revascularization after PDL treatment in a single-patient case report. The patient was a 56-year-old male with an extensive PWS who began to experience thickening and nodularity of his PWS necessitating surgical debulking after initial improvement with PDL alone. Topical sirolimus 0.5 percent ointment was added to his treatment regimen as an adjunct to PDL.

The researchers found that the patient experienced significant improvement in the color and texture of his PWS. Topical sirolimus ointment as an adjunct correlated with greater improvement and maintenance of therapeutic results compared with the initial treatment of PDL alone, with fewer overall laser treatments.

"Topical sirolimus 0.5 percent ointment is a safe and effective adjunct to PDL in the treatment of PWS," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths